Intelligent Investor

Bionomics Limited (ASX: BNO) - Announcements

DELISTED - Current share price for BNO : $0.010

ASX company news and announcements for Bionomics Limited (BNO) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bionomics Limited (BNO) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bionomics Limited (BNO), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bionomics Limited (BNO)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Removal from Official List 28 Aug 2023 9:57AM $0.010 $0.010 $0.010 fallen by 0%
- Change in substantial holding 25 Aug 2023 12:43PM $0.010 $0.010 $0.010 fallen by 0%
- Suspension from Official Quotation 25 Aug 2023 8:02AM $0.010 $0.010 $0.010 fallen by 0%
- Quarterly Activities/Appendix 4C Cash Flow Report June 2023 31 Jul 2023 9:11AM $0.013 $0.010 $0.010 fallen by 23.08%
- Shareholder communication on the De-listing process 28 Jul 2023 9:27AM $0.014 $0.010 $0.010 fallen by 28.57%
- Bionomics announces voluntary delisting from ASX 25 Jul 2023 9:20AM $0.022 $0.010 $0.010 fallen by 54.55%
- Trading Halt 24 Jul 2023 9:03AM $0.022 $0.010 $0.010 fallen by 54.55%
- Notification of cessation of securities - BNO 7 Jul 2023 4:09PM $0.020 $0.010 $0.010 fallen by 50%
- Bionomics Announces Key Leadership Updates 3 Jul 2023 9:32AM $0.018 $0.010 $0.010 fallen by 44.44%
- Poster Presentation at the ASCP Annual Meeting 1 Jun 2023 9:16AM $0.021 $0.010 $0.010 fallen by 52.38%
- Corporate Presentation - May 2023 23 May 2023 9:24AM $0.023 $0.010 $0.010 fallen by 56.52%
- BNO announces establishment of At-The-Market Equity Program 8 May 2023 8:54AM $0.022 $0.010 $0.010 fallen by 54.55%
- Quarterly Activities/Appendix 4C Cash Flow Report Mar 2023 28 Apr 2023 4:33PM $0.022 $0.010 $0.010 fallen by 54.55%
- Enrolment in Ph2b ATTUNE Clinical Trial of BNC210 completed 27 Apr 2023 4:16PM $0.022 $0.010 $0.010 fallen by 54.55%
- Change in substantial holding 11 Apr 2023 2:02PM $0.020 $0.010 $0.010 fallen by 50%
- Change in substantial holding 11 Apr 2023 1:49PM $0.019 $0.010 $0.010 fallen by 47.37%
- Change in substantial holding 20 Mar 2023 6:13PM $0.025 $0.010 $0.010 fallen by 60%
- Response to ASX Aware Query 14 Mar 2023 10:07AM $0.031 $0.010 $0.010 fallen by 67.74%
- Response to ASX Price Query 9 Mar 2023 2:43PM $0.036 $0.010 $0.010 fallen by 72.22%
- PREVAIL Data Disclosure Presentation 9 Mar 2023 10:36AM $0.036 $0.010 $0.010 fallen by 72.22%
- Pause in Trading 9 Mar 2023 10:30AM $0.036 $0.010 $0.010 fallen by 72.22%
- Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S 9 Mar 2023 10:16AM $0.036 $0.010 $0.010 fallen by 72.22%
- Trading Halt 8 Mar 2023 11:55AM $0.036 $0.010 $0.010 fallen by 72.22%
- Pause in Trading 8 Mar 2023 10:48AM $0.035 $0.010 $0.010 fallen by 71.43%
- Notification regarding unquoted securities - BNO 23 Feb 2023 7:18PM $0.029 $0.010 $0.010 fallen by 65.52%

1 - 25 of 801 results

Page 1 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.